Iol Chemicals & Pharmaceuticals Ltd. · NSE:IOLCP
Iol Chemicals & Pharmaceuticals — Q4 FY2022 Earnings Presentation
25 slides from Iol Chemicals & Pharmaceuticals's earnings presentation, May 31, 2022
Slide 1: Investor Presentation Q4FY22
IOL Chemicals and Pharmaceuticals Limited Investor Presentation Q4FY22 May 2022
Slide 2: Disclaimer
Disclaimer This information may contain certain forward-looking statements/details in the current scenario, which is extremely dynamic and increasingly fraught with risks and uncertainties. Actual results, performances, achievements or sequence of events may be materially different from the views ex
Slide 3: About IOL Chemicals and Pharmaceuticals Limited
About IOL Chemicals and Pharmaceuticals Limited Incorporated in 1986, IOLCP is one of the leading Pharmaceuticals company and is a significant player in the field of specialty chemicals with world class facilities Catering to the top-tier players across diverse important industries like pharmaceutic
Slide 4: Key Highlights
Key Highlights Team size of 2,300+ Largest producer of Largest producer of Ethyl 2nd Largest producer of Over 20 products are employees Ibuprofen and the only Acetate at Single Location Iso Butyl Benzene (IBB) commercialised with 12 company worldwide being in India with ~30% Global share products in
Slide 5: Professional Management Team
Professional Management Team Mr. Varinder is an industrialist and has wide and rich Mr. Vikas is academically equipped with the experience of more than 35 years in the chemical & knowledge and possesses organizational capacity. He fertilizer industry and along with a comprehensive has worked in stra
Slide 6: Experienced Independent Directors
Experienced Independent Directors • Mr. Rajender has very distinguished career of four • Mr. Harpal has had over 35 year's experience of banking decades. and financial services. • He had held top and significant decision-making • Most recently he was General Manager of Punjab positions in Banks, Fin
Slide 7: Our Journey
Our Journey Unit-08 & Unit- Unit-06 for Conversion of 10* for Multi Pantoprazole Unit-2 as Dedicated USFDA, EIR for 2022 Products 2020 (Dedicated) 2018 facility for Ibuprofen 2016 2013 Ibuprofen Commenced Unit-07 Metformin Unit-04 Metformin Received EUGMP 2021 2019 2017 Unit-03 for new 2015 commerci
Slide 8: Certifications and Accreditations
Certifications and Accreditations Approved USFDA facility since EUGMP Certification in 2013, Certificate of Suitability from Certified Halal in accordance 2015, recertified in 2019 2017 & Recertification in 2020 Certificate of DMF Registration EDQM with Shariah Board Guidelines From MFDS Korea Certi
Slide 9: Product Segmentation
Product Segmentation 9
Slide 10: Business Segment – Pharmaceuticals
Business Segment – Pharmaceuticals IOLCP is the largest producer of Ibuprofen with ~35% Global share and the only company worldwide being backward integrated for all Intermediates and Key Starting Material of Ibuprofen Among the largest Added 8 new products in Product portfolio that producer of Metf
Slide 11: Pharmaceuticals Product Portfolio
Pharmaceuticals Product Portfolio API API – Pipeline/ Validation Ibuprofen Irbesartan Ibuprofen Lysinate Valsartan Ibuprofen Sodium Vildagliptin Dex-Ibuprofen Sitagliptin M Phosphate Metformin HCL Quetiapine Fumarate Clopidogrel Bisulphate (Form II) Allopurinol Pantoprazole Sodium Minoxidil Fenofibr
Slide 12: Business Segment – Specialty Chemicals
Business Segment – Specialty Chemicals IOLCP first commenced manufacturing Ethyl Acetate in 1996, with a starting capacity of 3000 tonnes per annum. Today, the Company has grown this business to become the largest single location plant in India, with a production capacity of 100,000 tonnes per annum
Slide 13: Product wise Revenue Segmentation – Quarterly
Product wise Revenue Segmentation – Quarterly Q4FY22 Q3FY22 Q4FY21 572 555 460 96 50 112 20% 17% 11% 277 299 242 48% 168 160 54% 53% 183 37% 29% 32% Chemicals Ibuprofen Other API’s 13 All figures in INR crs unless stated
Slide 14: Product wise Revenue Segmentation – Yearly
Product wise Revenue Segmentation – Yearly FY22 FY21 2184 1967 351 206 16% 10% 798 1181 41% 652 54% 30% 963 49% Chemicals Ibuprofen Other API’s 14 All figures in INR crs unless stated
Slide 15: Manufacturing Facility spread across over 111 acres
Manufacturing Facility spread across over 111 acres with GMP approved guidelines API manufactured in batch manner and Facility is coupled with ISO class-8 HVAC intermediates & Specialty chemicals in Dedicated blocks involved in manufacturing system, PSA Nitrogen & Purified water along continuous pro
Slide 16: Our Core Sustainability Pillars
Our Core Sustainability Pillars • Strive to minimize the adverse impact on • Construction and renovation of school locations, environment, health and Safety by upgrading provided technical equipment for smart education technology, optimum utilization of resources and • Primary healthcare including s
Slide 17: Financial Overview
Financial Overview 17
Slide 18: Key Financial Summary
Key Financial Summary Financial Summary Q4FY22 Q3FY22 Q4FY21 FY22 FY21 (INR Cr) Total Income 579 564 467 2,216 1,991 Gross Profit 151 163 189 646 888 EBITDA 50 68 117 288 616 PAT 28 40 75 166 445 18 All Profits and Total Income include Other Income
Slide 19: 5 years Financial Performance - Annually
5 years Financial Performance - Annually Revenues & Margins* – Annual 2,216 50% 1,911 1,991 45% 2,000 38% 44% 45% 40% 1,696 31% 35% 1,500 30% 30% 25% 31% 29% 990 25% 1,000 20% 14% 22% 19% 15% 13% 13% 500 10% 7% 5% 3% - 0% FY18 FY19 FY20 FY21 FY22 Total Income Gross Profits % EBITDA % PAT % Segmental
Slide 20: Quarterly & Annually Financial Performance
Quarterly & Annually Financial Performance Quarterly Revenues & Margins* Yearly Revenues & Margins* 2450 50% 45% 700 45% 2250 2216 45% 40% 40% 2050 1991 40% 600 564 579 35% 1850 35% 500 467 29% 29% 30% 1650 30% 26% 31% 400 25% 25% 1450 25% 20% 1250 22% 20% 300 15% 1050 16% 12% 13% 15% 200 9% 10% 850
Slide 21: Geographical Segmental Breakup – Annual & Quarter
Geographical Segmental Breakup – Annual & Quarter Annually Quarterly In INR crs In INR crs 1,638 1,355 1,250 1,038 38% 34% 31% 25% 633 647 645 613 36% 546 31% 413 394 350 26% 31% 318 178 143 143 FY18 FY19 FY20 FY21 FY22 Q4FY21 Q3FY22 Q4FY22 Domestic Export 21 *FY21 Covid Impact
Slide 22: Financial Summary – Balance Sheet
Financial Summary – Balance Sheet Balance Sheet (INR Crs) FY18 FY19 FY20 FY21 FY22 Shareholder's Funds 215.7 474.3 813.5 1260.4 1390.3 Debt 421.9 284 56 0 0 Other Long Term Liabilities 33.6 20.8 79.7 59.1 56.6 Other Current Liabilities 180.9 162.8 220.6 290.6 513.4 Equity & Liabilities 852.1 941.9 1
Slide 23: Financial Summary – Statement of Profit and Losses
Financial Summary – Statement of Profit and Losses P&L (INR Crs) FY18 FY19 FY20 FY21 FY22 Q4FY21 Q3FY22 Q4FY22 Revenues 983.3 1,685.3 1,894.5 1,967.0 2,184.0 460.4 555.1 572.5 Other Income 6.3 10.4 16.0 24.3 32.0 6.2 8.9 6.9 Total Income 989.6 1,695.7 1,910.5 1,991.3 2,216.0 466.6 564.0 579.4 Gross
Slide 24: Shareholding Information
Shareholding Information Stock Data (As on 31st March, 2022) Shareholding Pattern (%) Market Capitalization (₹) 2,077 Crs 53.1% 50.3% Face Value(₹) 10 43.7% 43.7% Share Price (₹) 353.8 EPS TTM (₹) 36.3 52-Week High (₹) 714.5 6.0% 3.2% 52-Week Low (₹) 315.9 Promoter Institutional Non-institutional Sy
Slide 25: Thank You
Thank You For further details: Mr. Pardeep Kumar Khanna , CFO Email: pardeepkhanna@iolcp.com Phone: +91-161-2225531-35
IOL Chemicals and Pharmaceuticals — Q4 FY2022 Earnings Presentation on 6ix